Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

VA Office of Research and Development: Clinical Trials & FDA Approval Profile

VA Office of Research and Development (Global / Institutional) sponsors 112 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 59 active protocols (43 recruiting now), 34 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.0%
Median Closed Enrollment vs National (145 pts)48 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for VA Office of Research and Development
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)112
Active Pipeline (Recruiting Now)59 (43)
Completed vs Stopped Early34 / 19 (17.0%)
Median Closed Actual Enrollment48 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by VA Office of Research and Development
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05931276CSP #2026 - Beta Blocker Dialyzability on Cardiovascular OutcomesPhase IIIRECRUITING
NCT05011383High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate CancersPhase IIRECRUITING
NCT05593497A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT InhPhase IIRECRUITING
NCT05212246Basal Cell Carcinoma Chemoprevention TrialPhase IIIRECRUITING
NCT04038502Carboplatin or Olaparib for BRcA Deficient Prostate CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the VA Office of Research and Development Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI